000			01399 a2200349 4500
005			20250514223241.0
264		0	_c20050628
008			200506s 0 0 eng d
022			_a0300-7995
024	7		_a10.1185/030079905X36477 _2doi
040			_aNLM _beng _cNLM
100	1		_aHanefeld, M
245	0	0	_aOutcome studies in type 2 diabetes. _h[electronic resource]
260			_bCurrent medical research and opinion _c2005
300			_aS41-8 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aCardiovascular Agents _xtherapeutic use
650	0	4	_aCardiovascular Diseases _xcomplications
650	0	4	_aClinical Trials as Topic
650	0	4	_aClofibric Acid _xtherapeutic use
650	0	4	_aDiabetes Mellitus, Type 2 _xcomplications
650	0	4	_aDiabetic Angiopathies _xdrug therapy
650	0	4	_aHumans
650	0	4	_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use
650	0	4	_aHypoglycemic Agents _xtherapeutic use
650	0	4	_aOutcome Assessment, Health Care
650	0	4	_aPlatelet Aggregation Inhibitors _xtherapeutic use
650	0	4	_aRisk Reduction Behavior
650	0	4	_aThiazolidinediones _xtherapeutic use
773	0		_tCurrent medical research and opinion _gvol. 21 Suppl 1 _gp. S41-8
856	4	0	_uhttps://doi.org/10.1185/030079905X36477 _zAvailable from publisher's website
999			_c15480936 _d15480936